Alemtuzumab: key for minimization of maintenance immunosuppression in reconstructive transplantation?
Minimization of immunosuppression has become the key effort in solid organ transplantation. Alemtuzumab, the humanized CD-52 monoclonal antibody, is an effective depleting agent increasingly used in transplantation trials. In this article, we summarize the current experience with alemtuzumab use in hand transplantation and discuss its role in current and future approaches toward minimization of maintenance immunosuppression in reconstructive transplantation.
Schneeberger
S
S
Center of Operative Medicine, Department of Visceral, Transplant and Thoracic Surgery, Innsbruck Medical University, Innsbruck, Austria. schneebergers@upmc.edu
Landin
L
L
Kaufmann
C
C
Gorantla
V S
VS
Brandacher
G
G
Cavadas
P
P
Lee
W P A
WP
Breidenbach
W C
WC
Margreiter
R
R